CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 187,665	$ 298,172
Short-term marketable securities	53,598	29,312
Receivables from collaborative arrangements	12,270	16,785
Prepaid clinical and development services	1,524	1,513
Other prepaid and current assets	6,281	7,682
Total current assets	261,338	353,464
Long-term marketable securities	18,776
Property and equipment, net	12,103	11,875
Operating lease assets	39,204	40,126
Future contingent milestone and royalty assets	194,200	194,200
Restricted cash	836	836
Other assets	12,093	6,899
Total assets	538,550	607,400
Current liabilities:
Accounts payable	2,663	1,554
Accrued personnel-related expenses	5,030	10,314
Accrued clinical and development expenses	5,022	4,932
Accrued general and administrative expenses	4,586	4,020
Operating lease liabilities	7,431	6,753
Deferred revenue	24	24
Other accrued liabilities	1,428	1,118
Total current liabilities	26,184	28,715
Long-term operating lease liabilities	43,763	45,407
Future royalty payment contingency	25,988	25,438
Long-term deferred revenue	187	192
Unrecognized tax benefits	64,191	64,191
Other long-term liabilities	7,678	1,657
Commitments and contingencies
Shareholders' Equity
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 60,542 and 65,227 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	1	1
Additional paid-in capital	1,246,506	1,295,725
Accumulated other comprehensive income (loss)	51	(15)
Accumulated deficit	(875,999)	(853,911)
Total shareholders' equity	370,559	441,800
Total liabilities and shareholders' equity	$ 538,550	$ 607,400